Early proof-of-concept studies presented show RAD001 (everolimus) may offer a novel treatment strategy for breast cancer by enhancing the efficacy of, and overcoming resistance to, several commonly used breast cancer treatments. Findings from a Phase II study show that RAD001 enhances tumor shrinkage when given in combination with letrozole tablets (Femara(R)) to postmenopausal women with newly diagnosed estrogen receptor-positive (ER+) breast cancer.
More...